|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current asset: | |||||||||
| Cash | |||||||||
| Prepayments and deposits | |||||||||
| Total current assets | |||||||||
| Cash and investments held in trust account | |||||||||
| TOTAL ASSETS | |||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | |||||||||
| Current liabilities: | |||||||||
| Accrued liabilities | |||||||||
| Amount due to related party | |||||||||
| Promissory notes – related party | |||||||||
| Ordinary shares subject to redemption | |||||||||
| Total current liabilities | |||||||||
| Deferred underwriting compensation | |||||||||
| TOTAL LIABILITIES | |||||||||
| Ordinary shares subject to possible redemption 1,555,260 and 3,062,517 shares issued and outstanding at redemption value of $11.15 and $10.80 on June 30, 2026 and December 31, 2025, respectively | |||||||||
| Ordinary shares, $0.001 par value; 50,000,000 shares authorized; 1,963,000 and 1,963,000 shares issued and outstanding (excluding 1,555,260 and 3,062,517 shares, subject to possible redemption as of June 30, 2026 and December 31, 2025, respectively) | |||||||||
| Accumulated deficit | |||||||||
| Total Shareholders’ deficit | |||||||||
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT |
Loading...
